Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

Comparative Study of ALX-0081 Versus GPIIb/IIIa Inhibitor in High Risk Percutaneous Coronary Intervention (PCI) Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01020383
Recruitment Status : Completed
First Posted : November 24, 2009
Last Update Posted : January 4, 2019
Information provided by (Responsible Party):

Tracking Information
First Submitted Date  ICMJE November 23, 2009
First Posted Date  ICMJE November 24, 2009
Last Update Posted Date January 4, 2019
Study Start Date  ICMJE September 2009
Actual Primary Completion Date April 2011   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: November 23, 2009)
Incidence and severity of bleeding classified by the following criteria: TIMI major bleeding events, TIMI minor bleeding events, bleeding events requiring medical attention, defined as TIMI minimal bleeding events [ Time Frame: 30 days ]
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT01020383 on Archive Site
Current Secondary Outcome Measures  ICMJE Not Provided
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
Descriptive Information
Brief Title  ICMJE Comparative Study of ALX-0081 Versus GPIIb/IIIa Inhibitor in High Risk Percutaneous Coronary Intervention (PCI) Patients
Official Title  ICMJE A Phase 2 Randomized, Open Label Clinical Trial in High Risk Percutaneous Coronary Intervention (PCI) Patients Receiving Standard Antithrombotic Treatment Plus Either ALX-0081 or GPIIb/IIIa Inhibitor (ReoPro®) Over a Period of 24 Hours
Brief Summary

This is a multicenter, randomized and open-label Phase II study to compare the safety, tolerability and biological effectiveness of ALX-0081 versus the GPIIb/IIIa inhibitor ReoPro® in high risk PCI patients.

Patients will receive standard treatment with acetylsalicylic acid (ASA) plus clopidogrel and heparin. Eligible patients will be randomly assigned to receive open-label study treatment with either ALX-0081 or ReoPro®. Patients will be stratified according to PCI type (elective or ad-hoc) and stent type (bare metal stent or drug eluting stent).

Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Unstable Angina
  • Non ST Segment Elevation Myocardial Infarction (NSTEMI)
  • Stable Angina (Associated With High Risk PCI)
Intervention  ICMJE
  • Drug: ALX-0081
    4 i.v. bolus injections, once every 6 hours; first dose of 6 mg, three subsequent doses of 4 mg
  • Drug: ReoPro®
    0.25 mg/kg i.v. bolus injection followed by continuous i.v. infusion of 0.125 µg/kg/min (to a max. of 10 µg/min) for 12 hours
Study Arms  ICMJE
  • Experimental: ALX-0081
    Intervention: Drug: ALX-0081
  • Active Comparator: GPIIb/IIIa inhibitor
    Intervention: Drug: ReoPro®
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: July 11, 2012)
Original Estimated Enrollment  ICMJE
 (submitted: November 23, 2009)
Actual Study Completion Date  ICMJE March 2012
Actual Primary Completion Date April 2011   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Have unstable angina or NSTEMI,or stable angina with at least 2 factors indicating a high risk PCI as follows: patient related: diabetic patients, renal failure (glomerular filtration rate < 60), reduced left ventricular ejection fraction < 35%, age > 75 years, female gender and/or lesion/anatomy related: SYNTAX score > 26, bifurcation lesions, multi-vessel disease, intracoronary thrombus.
  • Adequate hematological function including platelets > 100000/mm3.
  • Body mass index (BMI) ≥18 kg/m2 and ≤ 35 kg/m2.
  • Aged ≥ 18 years old.
  • Women of childbearing potential must be practicing a medically acceptable contraceptive regimen. Only males who do not want to father children during the study and in the first 4 months after treatment may be included in the study. During this period, safe contraception is mandatory. Male patients who are sexually active must use a condom during intercourse and ensure that the female partner uses a reliable contraceptive method, or they must refrain from sexual intercourse during the first 4 months after treatment.
  • Patients must be accessible for follow-up.
  • Have a sufficient command to read and understand all instructions necessary for giving informed consent and participating in the study.
  • Have signed and dated written informed consent prior to any study-related procedures.

Exclusion Criteria:

  • Previous (within 30 days) treatment with GPIIb/IIIa inhibitors (such as ReoPro®).
  • ST-elevation myocardial infarction (STEMI).
  • Chronic total occlusion of a coronary artery.
  • Scheduled rotablator procedure.
  • PCI of the arterial or venous by-pass graft.
  • Any contra-indication for ReoPro®.
  • Major organ dysfunction, infection or any serious underlying medical condition that would impair the ability of the patient to receive protocol treatment.
  • Known hypersensitivity to human/humanized antibodies.
  • Women who are pregnant or lactating.
  • Dementia or significantly altered mental status that would prohibit understanding the study procedures and giving informed consent.
  • Use of vitamin K antagonists and/or Factor Xa inhibitors within 4 weeks prior to admission to the Hospital Intensive Care Unit.
  • Use of GPIIa/IIIb inhibitors other than ReoPro®; prasugrel, bivalirudin and fondaparinux prior to and throughout the study.
  • Known history of acquired or congenital bleeding disorder, coagulopathy or platelet disorder.
  • Evidence of active pathological bleeding at screening or history of clinically significant bleeding (such as gastrointestinal or genitourinary) within the last 6 months prior to screening visit, unless the cause has been definitely corrected
  • History of intracranial bleeding (e.g. hemorrhagic stroke, subdural hematoma, subarachnoid hemorrhage) or history of hemorrhagic retinopathy.
  • History of ischemic stroke or TIA, within the past year prior to screening or known structural cerebral vascular lesion (e.g. arteriovenous malformation, aneurysm).
  • History of New York Heart Association class III or IV congestive heart failure or history of severe, uncontrolled cardiac arrhythmias at screening.
  • Planned elective surgical operation or major invasive procedures or traumas from 30 days prior to screening to completion of the study at Day 30 (the decision of what constitutes a major invasive procedure or trauma will be at the discretion of the investigator in conjunction with review and approval by the Medical Monitor).
  • Use of another investigational drug or device within previous 30 days (12 weeks for investigational devices, e.g. unapproved stents) prior to screening.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Austria,   Belgium,   Czechia,   Germany,   Israel,   Poland,   Switzerland
Removed Location Countries Czech Republic
Administrative Information
NCT Number  ICMJE NCT01020383
Other Study ID Numbers  ICMJE ALX-0081-2.1/09
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Ablynx
Study Sponsor  ICMJE Ablynx
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Josefin-Beate Holz, MD Ablynx NV
PRS Account Ablynx
Verification Date January 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP